Back to Authors

Banatwala, Azeem

https://orcid.org/0000-0002-3464-4897

Mayo Clinic

Analysis Group (United States)

Citations 4

Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States
Cheng, Mu , DerSarkissian, Maral , Dabora, Jonathan, Young, Melanie , Noga, Stephen J. , Pi, Selina , Banatwala, Azeem , Duh, Mei Sheng , Cherepanov, Dasha , Ailawadhi, Sikander , Zhang, Melody

Journal of Managed Care & Specialty Pharmacy | September 9, 2024 | Volume: 30 | Issue: 12 | Pages: 1431-1441

10.18553/jmcp.2024.24085 Get It

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Sanchez, Larysa , Cheng, Mu, Cherepanov, Dasha , DerSarkissian, Maral , Stull, Dawn Marie, Dabora, Jonathan, Young, Melanie , Noga, Stephen J. , Pi, Selina , Banatwala, Azeem , Duh, Mei Sheng , Chari, Ajai , Chari, Ajai , Huang, Fei, Zhang, Melody , Ailawadhi, Sikander

Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 11 | Pages: 1205-1218

10.18553/jmcp.2023.23031 Get It

Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States
Singer, David , Thompson‐Leduc, Philippe , Gupta, Deepshekhar , Poston, Sara , Cheng, Wendy Y. , Ma, Siyu , Pawlowski, John E. , Duh, Mei Sheng , Devine, Francesca , Banatwala, Azeem , Bernstein, Emma , Farraye, Francis A. , Farraye, Francis A

Crohn's & Colitis 360 | July 12, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad033 Get It

Abstract Background Patients with ulcerative colitis (UC) or Crohn’s disease (CD) are at increased risk of herpes zoster (HZ); however, relevant cost and healthcare resource utilization (HCRU) data are limited. Methods We estimated HCRU (hospitalization, emergency department [ED], and outpatient visits) and costs in patients with UC or CD, with and without HZ, using administrative claims data (October 2015–February 2020). HCRU and costs (2020 US dollars) were compared at 1 month, 1 quarter, and 1 year after the index date, using propensity score adjustment and generalized linear models. Results In total, 20 948 patients were included: UC+/HZ+ (n = 431), UC+/HZ– (n = 10 285), CD+/HZ+ (n = 435), and CD+/HZ– (n = 9797). Patients with HZ had higher all-cause HCRU rates and all-cause total healthcare costs relative to those without HZ. In the first month, adjusted incidence rate ratios (aIRRs) for hospitalizations and ED visits for patients with UC and HZ compared with UC alone were 2.87 (95% confidence interval [CI], 1.93–4.27) and 2.66 (95% CI,1.74–4.05), respectively; for those with CD and HZ, aIRRs were 3.34 (95% CI, 2.38–4.70) and 3.31 (95% CI, 2.32–4.71), respectively, compared with CD alone (all P < .001). Adjusted cost differences in UC and CD cohorts with HZ over the first month were $2189 and $3774, respectively, chiefly driven by higher inpatient costs. The incremental impact on HCRU and costs in cohorts with HZ predominantly occurred during the first quarter following diagnosis. Conclusions HZ is associated with increased HCRU and costs in patients with UC and CD, especially shortly after diagnosis.
S894 Burden of Herpes Zoster Among Patients With Ulcerative Colitis and Crohn’s Disease in the United States: A Retrospective Cohort Study Using a Large Administrative Claims Database
Thompson‐Leduc, Philippe , Poston, Sara , Gupta, Deepshekhar , Ma, Siyu , Pawlowski, John E. , Duh, Mei Sheng , Banatwala, Azeem , Bernstein, Emma , Singer, David , Cheng, Wendy Y. , Devine, Francesca , Farraye, Francis A.

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S420-S420

10.14309/01.ajg.0000777108.73669.4f Get It